Selegiline (Fig. 48), a selective monoamine oxidase-B inhibitor, was suggested for neurodegenerative disease treatment due to its possible antioxidant properties in addition to rapid generation of the potent vasodilator nitric oxide in cerebral blood vessels.273 In 1997, it was reported to protect neurons and decrease the progression rate of AD in patients with moderately severe impairment from AD.258 In 2000, the analysis of 15 clinical trials revealed that there was no solid evidence to identify selegiline as a potential treatment for AD.261. The gene discussed is MAOB; the disease is neurodegenerative disease.